Program Updates

The Yale Program in Addiction Medicine, founded in 2017, seeks to extend and improve services for the prevention and treatment of substance use and substance use disorders. Constructed on four pillars—research, education, clinical practice, and policy—the program comprises an interprofessional faculty spanning several schools at Yale University, including the Yale School of Medicine (YSM); the Yale School of Public Health (YSPH); the Yale School of Nursing; and the Yale Law School. The program is aligned with the section of General Internal Medicine but has core faculty in other sections within the department, including Infectious Diseases, Digestive Diseases, and Pulmonary, Critical Care and Sleep Medicine, as well as faculty from the Department of Emergency Medicine.

The program has developed, researched, and disseminated innovations that shape the way in which addiction treatment is provided nationwide in primary care, emergency departments, hospitals, and HIV specialty settings, with ongoing research in obstetrical and hepatology settings. Educational initiatives train the next generation of generalists and addiction specialists. Faculty contributions to local, state, national, and international initiatives inform policy decisions related to the overdose epidemic, changes in cannabis and tobacco regulation, and other issues. Select achievements in the last year include expanded NIH HEAL Initiative funding; establishment of the IMPOWR-YOU Center; expansion of the YNHH Yale Addiction Medicine Consult Service; and extension of the program’s Addiction Medicine Rounds to a global audience. In addition, the program launched new educational partnerships with the University of Jordan in which faculty from the university, including Mayyada Wazaify, PhD, Professor of Pharmacy Practice, University of Jordan, presented to YSM medical students (pictured above).

With 18 core laboratories, the Yale Cardiovascular Research Center (YCVRC) is dedicated to discoveries to advance the prevention and treatment of cardiovascular disease. Established in 2008, the YCVRC houses basic and translational scientists with primary appointments in Cardiovascular Medicine who work to improve our fundamental understanding of cellular and molecular mechanisms as well as the physiology of the heart and vasculature. Major areas of research include cell and developmental biology, signaling, genetics, epigenetics, and metabolism. Co-directed by a unique leadership council (Anne Eichmann, PhD; Daniel Greif, MD; Kathleen Martin, PhD; and Stefania Nicoli, PhD), the YCVRC is a community of collaborative investigators that provides a supportive environment for nearly 100 trainees. The YCVRC infrastructure facilitates access to cutting-edge technologies, including high-resolution confocal microscopy; advanced DNA sequencing and bioinformatics; and artificial intelligence and machine learning, as well as induced human pluripotent stem cells and other sophisticated cardiovascular disease models.